Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure
Angiotensin-converting enzyme (ACE) inhibition is currently the cornerstone of congestive heart failure (CHF) therapy, but these drugs are not tolerated in up to 20% of patients. For these patients, therapeutic alternatives with comparable efficacy are needed. Felodipine, a vasoselective dihydropyri...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 1995-12, Vol.76 (17), p.1253-1258 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1258 |
|---|---|
| container_issue | 17 |
| container_start_page | 1253 |
| container_title | The American journal of cardiology |
| container_volume | 76 |
| creator | de Vries, Rob J.M. Quere, Michel Lok, Dirk J.A. Sijbring, Pieter Bucx, Jeroen J.J. van Veldhuisen, Dirk J. Dunselman, Peter H.J.M. |
| description | Angiotensin-converting enzyme (ACE) inhibition is currently the cornerstone of congestive heart failure (CHF) therapy, but these drugs are not tolerated in up to 20% of patients. For these patients, therapeutic alternatives with comparable efficacy are needed. Felodipine, a vasoselective dihydropyridine calcium antagonist with a slow onset of action and a long plasma half-life, may be such an agent. Therefore, the efficacy and safety or felodipine were examined and compared with enalpril using a double-blind design. We studied 46 patients with a left ventricular ejection fraction |
| doi_str_mv | 10.1016/S0002-9149(99)80352-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_230354679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000291499980352X</els_id><sourcerecordid>8942106</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-6e0ac948a1de147d1a5de48d2c6639db204841a42c1eebd453c2ee4bf7e7c2373</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EKtPCI1SyEAsqNWAnzo9XCI34kyqxAKTurDv2dcclsVM7Kcyr8LQ4M6PZsrKuzufj63MIueTsLWe8efedMVYWkgv5RsqrjlV1Wdw-ISvetbLgkldPyeqEPCfnKd3nkfO6OSNnbc0qxpoV-bsOwwjRpeBpsBStRT0lmqcR4RcNf3Z36KkOPs3DOLngr-nDDL2bdgveO4vXFLyhHucYtiEOwWNaJIt9MG50Hvc6euhhjK6nLlvD5NDnZ367abuY32Ga3CPSLUKcqAXXzxFfkGcW-oQvj-cF-fnp44_1l-Lm2-ev6w83hRa8mYoGGWgpOuAGuWgNh9qg6Eypm6aSZlMy0QkOotQccWNEXekSUWxsi60uq7a6IK8OvmMMD3PeRN2HOeZ9kyqrHKtoWpmh-gDpGFKKaFX-zABxpzhTSx9q34dawlZSqn0f6jbfuzyaz5sBzenWsYCsvz7qkDT0NoLXLp2wUrYsW2Xs_QHDHMSjw6iSzhFqNC7mwpQJ7j-L_APCTqrR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230354679</pqid></control><display><type>article</type><title>Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>de Vries, Rob J.M. ; Quere, Michel ; Lok, Dirk J.A. ; Sijbring, Pieter ; Bucx, Jeroen J.J. ; van Veldhuisen, Dirk J. ; Dunselman, Peter H.J.M.</creator><creatorcontrib>de Vries, Rob J.M. ; Quere, Michel ; Lok, Dirk J.A. ; Sijbring, Pieter ; Bucx, Jeroen J.J. ; van Veldhuisen, Dirk J. ; Dunselman, Peter H.J.M.</creatorcontrib><description>Angiotensin-converting enzyme (ACE) inhibition is currently the cornerstone of congestive heart failure (CHF) therapy, but these drugs are not tolerated in up to 20% of patients. For these patients, therapeutic alternatives with comparable efficacy are needed. Felodipine, a vasoselective dihydropyridine calcium antagonist with a slow onset of action and a long plasma half-life, may be such an agent. Therefore, the efficacy and safety or felodipine were examined and compared with enalpril using a double-blind design. We studied 46 patients with a left ventricular ejection fraction <0.40, peak oxygen consumption <20 ml-min
−1·kg
−1, and symptoms of CHF despite therapy with diuretics and digoxin. After 16 weeks of therapy, there were no statistically significant differences in peak oxygen consumption (felodipine +1.6, enalapril +2.5 ml·min
−1·kg
−1) and exercise tolerance (felodipine +61 seconds, enalapril +64 seconds). Quality-of-life parameters were affected slightly better by felodipine man by enalapril. Plasma norepinephrine decreased by 143 pg·ml
−1 with enalapril and by 12 pg·ml
−1 with felodipine (p > 0.20 between groups). Both drugs were generally well tolerated. These data suggest that felodipine and enalapril have comparable effects on exercise parameters in patients with CHF. Neurohumoral activation was not observed with either drug.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/S0002-9149(99)80352-X</identifier><identifier>PMID: 7503006</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Aldosterone - blood ; Angiotensin-Converting Enzyme Inhibitors - adverse effects ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Biological and medical sciences ; Calcium Channel Blockers - adverse effects ; Calcium Channel Blockers - pharmacology ; Calcium Channel Blockers - therapeutic use ; Cardiology. Vascular system ; Cardiovascular disease ; Double-Blind Method ; Drug therapy ; Enalapril - adverse effects ; Enalapril - therapeutic use ; Exercise Tolerance - drug effects ; Felodipine - adverse effects ; Felodipine - pharmacology ; Felodipine - therapeutic use ; Female ; Heart ; Heart attacks ; Heart Failure - blood ; Heart Failure - drug therapy ; Heart Failure - physiopathology ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Humans ; Male ; Medical research ; Medical sciences ; Middle Aged ; Norepinephrine - blood ; Oxygen Consumption - drug effects ; Quality of Life ; Renin - blood ; Vasodilator Agents - adverse effects ; Vasodilator Agents - pharmacology ; Vasodilator Agents - therapeutic use</subject><ispartof>The American journal of cardiology, 1995-12, Vol.76 (17), p.1253-1258</ispartof><rights>1995</rights><rights>1996 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Dec 15, 1995</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-6e0ac948a1de147d1a5de48d2c6639db204841a42c1eebd453c2ee4bf7e7c2373</citedby><cites>FETCH-LOGICAL-c416t-6e0ac948a1de147d1a5de48d2c6639db204841a42c1eebd453c2ee4bf7e7c2373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S000291499980352X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2970803$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7503006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Vries, Rob J.M.</creatorcontrib><creatorcontrib>Quere, Michel</creatorcontrib><creatorcontrib>Lok, Dirk J.A.</creatorcontrib><creatorcontrib>Sijbring, Pieter</creatorcontrib><creatorcontrib>Bucx, Jeroen J.J.</creatorcontrib><creatorcontrib>van Veldhuisen, Dirk J.</creatorcontrib><creatorcontrib>Dunselman, Peter H.J.M.</creatorcontrib><title>Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Angiotensin-converting enzyme (ACE) inhibition is currently the cornerstone of congestive heart failure (CHF) therapy, but these drugs are not tolerated in up to 20% of patients. For these patients, therapeutic alternatives with comparable efficacy are needed. Felodipine, a vasoselective dihydropyridine calcium antagonist with a slow onset of action and a long plasma half-life, may be such an agent. Therefore, the efficacy and safety or felodipine were examined and compared with enalpril using a double-blind design. We studied 46 patients with a left ventricular ejection fraction <0.40, peak oxygen consumption <20 ml-min
−1·kg
−1, and symptoms of CHF despite therapy with diuretics and digoxin. After 16 weeks of therapy, there were no statistically significant differences in peak oxygen consumption (felodipine +1.6, enalapril +2.5 ml·min
−1·kg
−1) and exercise tolerance (felodipine +61 seconds, enalapril +64 seconds). Quality-of-life parameters were affected slightly better by felodipine man by enalapril. Plasma norepinephrine decreased by 143 pg·ml
−1 with enalapril and by 12 pg·ml
−1 with felodipine (p > 0.20 between groups). Both drugs were generally well tolerated. These data suggest that felodipine and enalapril have comparable effects on exercise parameters in patients with CHF. Neurohumoral activation was not observed with either drug.</description><subject>Aged</subject><subject>Aldosterone - blood</subject><subject>Angiotensin-Converting Enzyme Inhibitors - adverse effects</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Calcium Channel Blockers - adverse effects</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular disease</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Enalapril - adverse effects</subject><subject>Enalapril - therapeutic use</subject><subject>Exercise Tolerance - drug effects</subject><subject>Felodipine - adverse effects</subject><subject>Felodipine - pharmacology</subject><subject>Felodipine - therapeutic use</subject><subject>Female</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Heart Failure - blood</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - physiopathology</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Humans</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Norepinephrine - blood</subject><subject>Oxygen Consumption - drug effects</subject><subject>Quality of Life</subject><subject>Renin - blood</subject><subject>Vasodilator Agents - adverse effects</subject><subject>Vasodilator Agents - pharmacology</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS0EKtPCI1SyEAsqNWAnzo9XCI34kyqxAKTurDv2dcclsVM7Kcyr8LQ4M6PZsrKuzufj63MIueTsLWe8efedMVYWkgv5RsqrjlV1Wdw-ISvetbLgkldPyeqEPCfnKd3nkfO6OSNnbc0qxpoV-bsOwwjRpeBpsBStRT0lmqcR4RcNf3Z36KkOPs3DOLngr-nDDL2bdgveO4vXFLyhHucYtiEOwWNaJIt9MG50Hvc6euhhjK6nLlvD5NDnZ367abuY32Ga3CPSLUKcqAXXzxFfkGcW-oQvj-cF-fnp44_1l-Lm2-ev6w83hRa8mYoGGWgpOuAGuWgNh9qg6Eypm6aSZlMy0QkOotQccWNEXekSUWxsi60uq7a6IK8OvmMMD3PeRN2HOeZ9kyqrHKtoWpmh-gDpGFKKaFX-zABxpzhTSx9q34dawlZSqn0f6jbfuzyaz5sBzenWsYCsvz7qkDT0NoLXLp2wUrYsW2Xs_QHDHMSjw6iSzhFqNC7mwpQJ7j-L_APCTqrR</recordid><startdate>19951215</startdate><enddate>19951215</enddate><creator>de Vries, Rob J.M.</creator><creator>Quere, Michel</creator><creator>Lok, Dirk J.A.</creator><creator>Sijbring, Pieter</creator><creator>Bucx, Jeroen J.J.</creator><creator>van Veldhuisen, Dirk J.</creator><creator>Dunselman, Peter H.J.M.</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>19951215</creationdate><title>Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure</title><author>de Vries, Rob J.M. ; Quere, Michel ; Lok, Dirk J.A. ; Sijbring, Pieter ; Bucx, Jeroen J.J. ; van Veldhuisen, Dirk J. ; Dunselman, Peter H.J.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-6e0ac948a1de147d1a5de48d2c6639db204841a42c1eebd453c2ee4bf7e7c2373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Aged</topic><topic>Aldosterone - blood</topic><topic>Angiotensin-Converting Enzyme Inhibitors - adverse effects</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Calcium Channel Blockers - adverse effects</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular disease</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Enalapril - adverse effects</topic><topic>Enalapril - therapeutic use</topic><topic>Exercise Tolerance - drug effects</topic><topic>Felodipine - adverse effects</topic><topic>Felodipine - pharmacology</topic><topic>Felodipine - therapeutic use</topic><topic>Female</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Heart Failure - blood</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - physiopathology</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Humans</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Norepinephrine - blood</topic><topic>Oxygen Consumption - drug effects</topic><topic>Quality of Life</topic><topic>Renin - blood</topic><topic>Vasodilator Agents - adverse effects</topic><topic>Vasodilator Agents - pharmacology</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Vries, Rob J.M.</creatorcontrib><creatorcontrib>Quere, Michel</creatorcontrib><creatorcontrib>Lok, Dirk J.A.</creatorcontrib><creatorcontrib>Sijbring, Pieter</creatorcontrib><creatorcontrib>Bucx, Jeroen J.J.</creatorcontrib><creatorcontrib>van Veldhuisen, Dirk J.</creatorcontrib><creatorcontrib>Dunselman, Peter H.J.M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Vries, Rob J.M.</au><au>Quere, Michel</au><au>Lok, Dirk J.A.</au><au>Sijbring, Pieter</au><au>Bucx, Jeroen J.J.</au><au>van Veldhuisen, Dirk J.</au><au>Dunselman, Peter H.J.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>1995-12-15</date><risdate>1995</risdate><volume>76</volume><issue>17</issue><spage>1253</spage><epage>1258</epage><pages>1253-1258</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Angiotensin-converting enzyme (ACE) inhibition is currently the cornerstone of congestive heart failure (CHF) therapy, but these drugs are not tolerated in up to 20% of patients. For these patients, therapeutic alternatives with comparable efficacy are needed. Felodipine, a vasoselective dihydropyridine calcium antagonist with a slow onset of action and a long plasma half-life, may be such an agent. Therefore, the efficacy and safety or felodipine were examined and compared with enalpril using a double-blind design. We studied 46 patients with a left ventricular ejection fraction <0.40, peak oxygen consumption <20 ml-min
−1·kg
−1, and symptoms of CHF despite therapy with diuretics and digoxin. After 16 weeks of therapy, there were no statistically significant differences in peak oxygen consumption (felodipine +1.6, enalapril +2.5 ml·min
−1·kg
−1) and exercise tolerance (felodipine +61 seconds, enalapril +64 seconds). Quality-of-life parameters were affected slightly better by felodipine man by enalapril. Plasma norepinephrine decreased by 143 pg·ml
−1 with enalapril and by 12 pg·ml
−1 with felodipine (p > 0.20 between groups). Both drugs were generally well tolerated. These data suggest that felodipine and enalapril have comparable effects on exercise parameters in patients with CHF. Neurohumoral activation was not observed with either drug.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>7503006</pmid><doi>10.1016/S0002-9149(99)80352-X</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 1995-12, Vol.76 (17), p.1253-1258 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_journals_230354679 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Aged Aldosterone - blood Angiotensin-Converting Enzyme Inhibitors - adverse effects Angiotensin-Converting Enzyme Inhibitors - therapeutic use Biological and medical sciences Calcium Channel Blockers - adverse effects Calcium Channel Blockers - pharmacology Calcium Channel Blockers - therapeutic use Cardiology. Vascular system Cardiovascular disease Double-Blind Method Drug therapy Enalapril - adverse effects Enalapril - therapeutic use Exercise Tolerance - drug effects Felodipine - adverse effects Felodipine - pharmacology Felodipine - therapeutic use Female Heart Heart attacks Heart Failure - blood Heart Failure - drug therapy Heart Failure - physiopathology Heart failure, cardiogenic pulmonary edema, cardiac enlargement Humans Male Medical research Medical sciences Middle Aged Norepinephrine - blood Oxygen Consumption - drug effects Quality of Life Renin - blood Vasodilator Agents - adverse effects Vasodilator Agents - pharmacology Vasodilator Agents - therapeutic use |
| title | Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A16%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20effects%20on%20peak%20oxygen%20consumption,%20quality%20of%20life,%20and%20neurohormones%20of%20felodipine%20and%20enalapril%20in%20patients%20with%20congestive%20heart%20failure&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=de%20Vries,%20Rob%20J.M.&rft.date=1995-12-15&rft.volume=76&rft.issue=17&rft.spage=1253&rft.epage=1258&rft.pages=1253-1258&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/S0002-9149(99)80352-X&rft_dat=%3Cproquest_cross%3E8942106%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230354679&rft_id=info:pmid/7503006&rft_els_id=S000291499980352X&rfr_iscdi=true |